Tonix Pharmaceuticals Holding Corp.TNXPNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -31.68% | -2.14% | -9.51% | +16.58% | +108.75% |
| Gross Profit Growth | +0.00% | +80.78% | +0.00% | +51.78% | +209.65% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +23.57% | +134.52% | +79.37% | +43.63% | +276.02% |
| Weighted Average Shares Diluted Growth | +23.57% | +134.52% | +79.37% | +43.63% | +276.02% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +72.20% | +0.00% | +135.76% | -13.26% | +23.43% |
| Inventory Growth | -40.57% | -34.13% | -36.70% | -27.76% | -28.48% |
| Asset Growth | +5.46% | +42.50% | +166.49% | +165.76% | +70.16% |
| Book Value per Share Growth | +7.02% | -28.87% | +122.46% | +116.85% | -53.28% |
| Debt Growth | -46.00% | -94.27% | -94.84% | -95.11% | -75.30% |
| R&D Expense Growth | -51.54% | -42.19% | +11.57% | +1.92% | +104.18% |
| SG&A Expenses Growth | +53.82% | +8.53% | -100.00% | +0.00% | +128.96% |